Skip to main content
SpringerLink
Log in

Trastuzumab for six months cost effective in Iran

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. human epidermal growth factor receptor 2

  2. 2014−2017 euros

  3. high income countries

  4. middle income countries

Reference

  • Ansaripour A, et al. Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy. PharmacoEconomics : 9 Aug 2017. Available from: URL: http://doi.org/10.1007/s40273-017-0557-6

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Trastuzumab for six months cost effective in Iran. PharmacoEcon Outcomes News 785, 36 (2017). https://doi.org/10.1007/s40274-017-4286-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-017-4286-z

Search

Navigation